Investment
Features
FeesSafety
Academy
More
Pluang+

Hyperliquid closes $110.85M Bitcoin loss, opens Tesla and semiconductor longs ahead of earnings

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
Hyperliquid closes $110.85M Bitcoin loss, opens Tesla and semiconductor longs ahead of earnings

Hyperliquid closed a $110.85 million Bitcoin long position at a $3.26 million loss, involving 1,355.6 BTC. It then opened new perpetual long contracts linked to Tesla and two semiconductor ETFs (Roundhill Memory ETF and Direxion Daily Semiconductor Bull 3X ETF) ahead of Tesla's Q3 earnings report. These contracts provide price exposure without ownership of Tesla shares. Tesla's earnings and Q&A webcast are scheduled for October 21 after market close. This move reflects strategic positioning ahead of key market events using Hyperliquid's HIP-3 framework for perpetual markets.

Hyperliquid's recent trading moves provide context for readers following cryptocurrency and tech-related assets. For readers following these markets, here is Pluang's market snapshot as of Oct 19, 2026 17:02 WIB: Among 50 major cryptocurrencies tradable on Pluang, 33 rose and 16 fell today. Notable price changes include Balancer (BAL) at Rp16.297 with an 11.14% increase, EOS.IO (EOS) at Rp12.649 up 8.13%, and The Sandbox (SAND) at Rp1.055 down 5.15%, with a typical hold time on Pluang of 123 days and Pluang order activity showing 35% Sell and 65% Buy.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
24 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
24 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
24 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
24 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
24 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App